Part V

Office of Science and Technology Policy

Proposed Model Federal Policy for Protection of Human Subjects; Response to the First Biennial Report of the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research; Notice
OFFICE OF SCIENCE AND TECHNOLOGY POLICY

Proposed Model Federal Policy for Protection of Human Subjects; Response to the First Biennial Report of the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research

AGENCY: Office of Science and Technology Policy, Executive Office of the President.

ACTION: Notice of proposed model policy for department/agency implementation.

SUMMARY: This Notice sets forth the Office of Science and Technology Policy response to the recommendations in the First Biennial Report of the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. This response, made on behalf of all affected federal departments and agencies, is based on the work of the Ad Hoc Committee for the Protection of Human Research Subjects and further deliberations of the Interagency Human Subjects Coordinating Committee. The First Biennial Report was published in the Federal Register on March 29, 1982 (47 FR 13272-13305). Responses of the Ad Hoc Committee were reviewed by the Science Advisor to the President and, with some modifications, accepted by affected department and agency heads in May 1985. This Notice includes in response to the first and most important recommendation, a Model Federal Policy for the Protection of Human Research Subjects (Model Policy) involved in research conducted, supported or regulated by federal departments and agencies. The Notice also contains a list of departments and agencies that intend to adopt the Model Policy and describes what, if any, departures from the Model Policy departments and agencies propose to make at the time of their policy implementation in order to meet particular statutory requirements or program needs.

Public comment and that of the federal departments and agencies is requested on the Proposed Model Policy, proposed department and agency departures, and other aspects of this Notice. Based upon these comments, a Final Model Policy will be published in the Federal Register. Each department and agency will expeditiously and in a coordinated fashion promulgate the Final Model Policy through its normal procedures for implementing such policies, e.g., through publication of regulations in the Federal Register.

DATES: Comments must be received on or before August 4, 1986. The Interagency Human Subjects Coordinating Committee will consider these comments and refer them to the Office of Science and Technology Policy for use in development of a Final Model Policy and to departments and agencies for use in their policy implementation.

ADDRESSES FOR COMMENT AND FURTHER INFORMATION: Comments and requests for further information should be addressed to: Joan P. Porter, Staff Director, Interagency Committee for the Protection of Human Subjects, Building 31, Room 4B09, Bethesda, Maryland 20892 (301-496-7041). Please specify which recommendations or sections of the Model Policy to which the comments pertain.

John P. McTague, Acting Director, Office of Science and Technology Policy.

SUPPLEMENTARY INFORMATION:

Table of Contents

- Background
- Office of Science and Technology Policy Response to the First Biennial Report of the President’s Commission
- Proposed Model Federal Policy for Protection of Human Research Subjects
- Agreed Concurrences of Department and Agency Heads and Proposed Departures from the Model Policy

Background

The President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research was established on November 9, 1978, by Pub. L. 95-622. One of the charges to the President’s Commission was to report biennially to the President, the Congress, and appropriate federal departments and agencies on the protection of human subjects of biomedical and behavioral research. In carrying out this charge, the President’s Commission was directed to conduct a review of the adequacy and uniformity (1) of the rules, policies, guidelines, and regulations of all federal departments and agencies regarding the protection of human subjects of biomedical or behavioral research. In carrying out this charge, the President’s Commission was directed to conduct a review of the adequacy and uniformity

In December 1981 the President’s Commission issued its First Biennial Report on the Adequacy and Uniformity of Federal Rules, Policies, and Procedures: Implementation, for the Protection of Human Subjects in Biomedical and Behavioral Research, Protecting Human Subjects. In transmitting the Report to the President, Morris B. Abram, Chairman of the Commission noted: The Commission does not propose any major organizational change, namely that a uniform core of regulations be adopted, based upon the present rules of the Department of Health and Human Services, and that HHS become the lead agency in this field. This consolidation would eliminate needless duplication in the rules of the 23 other Federal entities that support or regulate research, thereby simplifying both local compliance with the rules and Federal oversight of the system. Copies of this report are being sent to all affected Federal agencies, with a request for action, pursuant to the Commission’s enabling legislation.

In accord with Pub. L. 95-622, each federal department or agency which receives recommendations from the President’s Commission with respect to its rules, policies, guidelines or regulations, must publish these recommendations in the Federal Register and provide an opportunity for interested persons to submit written data, views and arguments with respect to adoption of the recommendations. On March 29, 1982, (47 FR 13272-13305) the Secretary, HHS, published the report on behalf of all the departments and agencies affected by the recommendations.

In May 1982 the Chairman of the Federal Coordinating Council for Science, Engineering and Technology (FCCSET), appointed an Ad Hoc Committee for the Protection of Human Research Subjects under the auspices of the FCCSET. The Committee, chaired by Dr. Edward N. Brandt, Jr., Assistant Secretary for Health, HHS, was composed of the representatives and Ex Officio members of affected departments and agencies. In consultation with the Office of Science and Technology Policy (OSTP) and the Office of Management and Budget, the Ad Hoc Committee, after considering all public comments, developed responses to the recommendations of the President’s commission. After further review and refinement, OSTP responded on behalf of all affected department and agency heads to the recommendations of the President’s Commission.
The first and most far-reaching recommendation of the President’s Commission resulted in the development of a Proposed Model Federal Policy for the Protection of Human Research Subjects based on the January 1981 HHS regulations for the protection of human subjects (45 CFR Part 46). The President should, through appropriate action, require that all federal departments and agencies adopt as a common core the regulations governing research with human subjects issued by the Department of Health and Human Services (codified at 45 CFR Part 46), as periodically amended or revised, while permitting additions needed by any department or agency that are not inconsistent with these core provisions.

The Ad Hoc Committee agreed that uniformity is desirable among departments and agencies to eliminate unnecessary regulation and to promote increased understanding and ease of compliance by institutions that conduct federally supported or regulated research involving human subjects. Therefore, the Ad Hoc Committee developed a Model Policy, which applies to research involving human subjects that is conducted, supported or regulated by federal departments and agencies. In accordance with the Commission’s recommendation, the Model Policy is based on Subpart A of the regulations of the Department of Health and Human Services (HHS) for the protection of human research subjects (45 CFR Part 46). The Proposed Model Policy developed by the Ad Hoc Committee was later modified by OSTP to enhance uniformity of implementation among the affected federal departments and agencies and to provide consistency with other related policies. The revised Policy was concurred in by all affected federal departments and agencies heads in March 1985.

The President’s Commission also recommended that the President authorize and direct the Secretary, HHS, to designate an office with governmentwide jurisdiction to coordinate, monitor and evaluate the implementation of all federal regulations governing research with human subjects. For the reasons set forth in its response, the Ad Hoc Committee recommended that the Office of Protection from Research Risks (OPRR), National Institutes of Health, serve in a federal coordinating role for the protection of human subjects. The Director, OPRR, chairs the Interagency Human Subjects Coordinating Committee described below.

The Proposed Model Policy and the other responses to the President’s Commission accepted by OSTP and the affected department and agency heads, are set forth below. After a public comment period and publication of a Final Model Policy, each department and agency will promulgate the Model Policy expeditiously through whatever procedures are normally utilized for the implementation of policies or regulations, e.g. through publication as regulations in the Federal Register. Instances in which the policies of certain departments and agencies propose to depart from the Model Policy during their rulemaking or other implementation processes to accommodate statutory or program requirements are also described herein.

The interagency Human Subjects Coordinating Committee was composed of representatives of all federal departments and agencies that conduct, support or regulate research involving human subjects. The Committee is advisory to department and agency heads and among other responsibilities, evaluates the implementation of the Model Policy and recommends changes as necessary. OSTP responses to the recommendations of the President’s Commission based on the report of the Ad Hoc Committee; the Proposed Model Policy; and the concurrences and intended departures of each affected federal department or agency head are presented below.

Response to Recommendations of the President’s Commission


This response is based on the work of the Ad Hoc Committee for the Protection of Human Research Subjects of the Federal Coordinating Council for Science, Engineering, and Technology which was modified to incorporate OSTP policy considerations in and accepted by affected Federal department and agency heads in June 1984.

Recommendation 1

The President should, through appropriate action, require that all federal departments or agencies adopt a common core the regulations governing research with human subjects issued by the Department of Health and Human Services (codified at 45 CFR Part 46), as periodically amended or revised, while permitting additions needed by any department or agency that are not inconsistent with these core provisions.

(A timetable of 180 days should be established by the President to provide an incentive for the interagency group to resolve any remaining questions about the HHS core regulations and identify an initial set of special rules beyond the core that are needed by various departments and agencies. If action is not prompt, the Commission suggests that Congress enact legislation directing the Executive branch to establish by a specified date a uniform set of regulations under a lead agency.)

The Ad Hoc Committee agreed in principle with this recommendation and developed a Model Federal Policy (Model Policy) statement based upon adaptations of HHS regulations for the protection of human subjects involved in research (45 CFR Part 46). The Office of Science and Technology Policy has made several modifications to increase uniformity of procedures among the federal departments and agencies and to increase compatibility with other current federal policies.

The Model Policy represented the Ad Hoc Committee’s attempt to meet the concerns of the Commission that unnecessary and confusing regulations impose burdens on institutions that conduct or support research involving human subjects. The Committee attempted to make the Model Policy consistent with the HHS regulations while allowing for flexibility and adaptability in its application to the programs of diverse federal departments and agencies.

The Ad Hoc Committee believed that, insofar as possible, federal departments and agencies should employ consistent policies and procedures in dealing with nonfederal research institutions. Accordingly, the Model Policy was drafted in a mode that strives for uniformity in assurance and certification procedures; in all matters pertaining to the establishment, membership, functions and responsibilities of Institutional Review Boards (IRBs); and in procedural requirements including informed consent. Nevertheless, the Model Policy will allow agencies to continue to utilize time-tested directives and procedures in the conduct of their intramural research so long as these procedures are consistent with the Model Policy and adequately protect the rights and welfare of human research subjects.
Similarly, the Policy is designed to apply to research conducted, supported or regulated by United States departments or agencies in foreign situations. However, department or agency heads may accept other recognized standards in lieu of this Policy so long as these standards offer at least equivalent protections for research subjects.

The Ad Hoc Committee concurred with the findings of the President’s Commission that there is already close correlation between the major provisions of the HHS regulations and current policies and procedures of other federal departments and agencies for protecting human subjects. The Model Policy is intended to further reduce the diversity so that nonfederal research institutions will not have to face inconsistent or contradictory requirements in their dealings with federal departments and agencies. The Ad Hoc Committee fully expected that adoption of the Policy will reduce the administrative burdens on institutions that conduct research involving human subjects.

The Model Policy document has been drafted in the form of a policy statement rather than in the form of a regulation so that it may be referenced by departments and agencies that will implement the Policy within a reasonable time and in a manner customary to each department or agency. In the future, department or agency heads may amend their policies so long as they note in advance in the Federal Register or other appropriate publication the way in which their amendments relate to provisions of the Model Policy.

Assuming a department or agency adopts the Model Policy it will retain the flexibility to waive individual requirements if waiver decisions are published in advance in the Federal Register or other appropriate publication. The Ad Hoc Committee believed that instances of waiver will be infrequent, and the requirement that each waiver be published will prevent inappropriate use of the waiver authority.

Highlights of key elements of the Model Policy for federal wide use are as follows:

Consistency with HHS Regulations

As noted previously, the Ad Hoc Committee Model Policy is patterned after HHS regulations. The word “Secretary” has been changed to “department or agency head” throughout the draft. Most of the provisions of the following subject areas are the same in the Model Policy and HHS regulations:

1. The characteristics of IRBs; (2) the role of IRBs in providing prior review of research protocols, including their duties and authorities in relation to investigators, to their institutions, and to the sponsors of research; (3) the standards and procedures that should govern the reviewing and investigators’ behavior; (4) the provisions of assuring compliance with the policy; (5) the procedures for expedited review; (6) the the provisions for obtaining and documenting informed consent; and (7) the provisions for early termination of research support and evaluation of applications. The following highlights the major areas in which there is a difference in the Model Policy and Current HHS regulations.

Applicability

Sec. 101(a) specifies that

. . . [The policy] includes research conducted, supported, or otherwise subject to regulation by the federal government outside the United States.

(1) Research that is conducted or supported by a federal department or agency whether or not it is regulated as defined in Sec. 102(e) must comply with all sections of this policy.

(2) Research that is neither conducted nor supported by a federal department or agency but is subject to regulation as defined in Sec. 102(e) must be reviewed and approved, in compliance with Secs. 101, 102 and 107 through 117 of this policy, by an institutional review board (IRB) that operates in accordance with the pertinent requirements of this policy.

It should be noted that federal support of an activity does not necessarily render the policy applicable to that activity. Federal “support” must be used in “research” involving “human subjects” as defined in the policy. For example, a private physician who conducts research unrelated to the Medicaid program would not come under this policy solely because the services he/she provides some of his/her patients are reimbursed by Medicaid. Nor would a research project sponsored by a State agency be covered solely because nonresearch services administered by the same agency are federally reimbursed. Alternatively, if a private physician or a State agency does employ federal support for research involving human subjects or if the physician or State agency voluntarily adopt this policy through the assurance mechanism, this policy would be applicable.

The Model Policy contains a definition of regulated research and indicates which sections of the policy are applicable to regulated research. Sec. 102(e) defines regulated research.

Research subject to regulation. ’ and similar terms are intended to encompass those research activities for which a federal department or agency has specific responsibility for regulating as a research activity, (for example, Investigational New Drug requirements administered by the Food and Drug Administration). It does not include research activities which are incidentally regulated by a federal department or agency solely as part of the department’s or agency’s broader responsibility to regulate certain types of activities whether research or non-research in nature (for example, Wage and Hour requirements administered by the Department of Labor).

The provision in the HHS regulations which allows the Secretary to waive certain provisions is adapted to the Model Policy in the following manner:

Sec. 101(i) provides that

Unless otherwise required by law, department or agency heads may waive the applicability of some or all of the provisions of this policy to specific research activities or classes of research activities otherwise covered by this policy. Except when otherwise required by statute or Executive Order, the department or agency head shall forward advance notices of these actions to the Office for Protection from Research Risks, Department of Health and Human Services (HHS), and shall also publish them in the Federal Register or in such other manner as provided in department or agency procedures.

Consequently, waiver determinations must normally be published in the Federal Register, thus subjecting them to public scrutiny.

Changes in Exemptions

Sec. 101(b) sets forth exemptions for certain research activities from coverage of the Model Policy. The Model Policy combines exemptions 45 CFR 46.101(b)(2), (3) and (4) of the HHS regulations dealing with the use of educational tests, survey and interview procedures and observation of public behavior. The HHS exemptions are reflected in Model Policy exemptions sec. 101(b)(2) and (3):

(2) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures or observation of public behavior, unless:

(i) information obtained is recorded in such a manner that human subjects can be identified, directly or through identifiers linked to the subjects; and

(ii) any disclosure of the human subjects’ responses outside the research could reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects’ financial standing or employability.

(3) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures,
interview procedures or observation of public behavior that is exempt under paragraph (2), if:

(i) the human subjects are elected or appointed public officials or candidates for public office; or

(ii) Federal statute(s) require(s) without exception that the confidentiality of the personally identifiable information will be maintained throughout the research and thereafter.

Thus, provision is made in the Model Policy for exempting certain social science research when federal statutes require without exception that the confidentiality of the personally identifiable information will be maintained.

Sec. 101(b)(6) is a new exemption

Taste and food quality evaluation studies, if wholesome foods without chemical additive are consumed or if a limited amount of a food is consumed that contains a food additive or agricultural chemical at or below a level approved by the Food and Drug Administration (FDA), the Environmental Protection Agency, or the Animal Plant Health Inspection Service of the U.S. Department of Agriculture.

This exemption, requested by the U.S. Department of Agriculture (USDA) but appropriate for several other agencies as well, is intended to exempt certain taste and food quality evaluation studies from IRB review. The current USDA policy exempts taste and food quality evaluation studies which involve consumer acceptance testing and quality evaluation studies if a limited amount of food will be consumed containing a food additive or agricultural chemical at a level approved by the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA) or the Animal Plant Health Inspection Service (APHIS) of the USDA; or if the food chemical is normally found in food at concentrations at least equal to those being tested. The exemption is not intended to apply to taste tests and quality evaluation studies if the food additive is being tested and the test chemical is not (1) on FDA’s Generally Recognized as Safe (GRAS) list; (2) a permitted food additive as tested; or (3) normally found in food at concentrations being tested. In addition, the exemption is not intended to apply if a pesticide or other chemical residue is present and the acceptable level has not been established by FDA, EPA or APHIS.

Foreign Research

Sec. 101(g) states clearly what is only implicit in the HHS regulations, namely that the Model Policy does not affect any foreign laws or regulations which may otherwise be applicable and which provide additional protections for human subjects. Furthermore, it allows department and agency heads discretion in accepting equivalent procedures for research carried out in foreign countries. Sec. 101(h) provides that

When research covered by this policy takes place in foreign countries, procedures normally followed in the foreign countries to protect human subjects may differ from those set forth in this policy. [An example is a foreign institution which complies with guidelines consistent with the 1975 World Medical Assembly Declaration (Helsinki II) issued either by sovereign states or by an organization whose function for the protection of human research subjects is internationally recognized.] In these circumstances, if a department or agency head determines that the procedures prescribed by the institution afford protections that are at least equivalent to those provided in this policy, the department or agency head may approve the substitution of the foreign procedures in lieu of the procedural requirements provided in this policy. Except when otherwise required by statute, Executive Order, or the department or agency head, notices of these actions as they occur will be published in the Federal Register or such other publications as provided by department or agency procedures. (Italics supplied)

Assuring Compliance with the Model Policy

Sec. 103(a) requires that

Each institution engaged in research which is covered by this policy and which is conducted or supported by a federal department or agency shall provide mitten assurance satisfactory to the department or agency head that it will comply with the requirements set forth in this policy.

Current HHS regulations permit institutions which hold an approved assurance to delay submission of certification of IRB review and approval until 60 days after submission of an application or proposal for financial support. As the Model Policy does not include a grace period.

Sec. 103(g) requires that

Certification is required when the research is supported by a federal department or agency and not otherwise exempted or waived under Secs. 101(b) or (i). Along with the submission of an application or proposal for approval or support, an institution with an approved assurance covering the research shall certify that the application or proposal has been reviewed and approved by the IRB. Institutions without an approved assurance covering the research shall certify within 30 days after receipt of a request for such a certification from the department or agency, that the application or proposal has been approved by the IRB. If the certification is not submitted within these time limits, the application or proposal may be returned to the institution.

IRB Membership

Sec. 107(a) includes a provision that . . . The IRB shall be sufficiently qualified through the experience and expertise of its members, and the diversity of the members including consideration of race, gender, and cultural backgrounds and sensitivity to such issues as community attitudes, to promote respect for its advice and counsel in safeguarding the rights and welfare of human subjects. . . .

Sec. 107(a) of the Model Policy also replaces the current HHS requirement that if an IRB regularly reviews research that involves a vulnerable category of subjects, the IRB must include one or more individuals who are primarily concerned with the welfare of those subjects. Consideration of inclusion of such an individual(s) is left to the, institution (or other authority) establishing the IRB in the Model Policy.

The Model Policy requires instead in 1079(a) that

If an IRB regularly reviews research that involves a vulnerable category of subjects, such as children, prisoners, pregnant women or mentally disabled persons, consideration shall be given to the inclusion of one or more individuals who are knowledgeable about and experienced in working with these subjects.

45 CFR 46.107(b) of the 1981 HHS regulations indicates that no IRB may consist entirely of men or entirely of women, or entirely of members of one profession.

Section 107(b) of the Model Policy reads

Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of men or entirely of women, including the institution’s consideration of qualified persons of both sexes, so long as no selection is made to the IRB on the basis of gender. No IRB may consist entirely of members of one profession.

This language was developed in consultation with the Department of Justice.

In seeking diverse membership on the IRB, the institution must consider both men and women who can contribute to the work of the IRB. Given the ready availability of well qualified persons of both genders, OSTP expects that only rarely, if ever, will an IRB consist solely of men or solely of women. In any event, no selection shall be made to the board on the basis of gender.

Recommendation 2

The President should authorize and direct the Secretary of Health and Human Services to designate an office with government-wide jurisdiction to coordinate, monitor and evaluate the implementation of all regulations governing research with human subjects
of Federal departments that conduct, support or regulate such research.

The Ad Hoc Committee endorsed the concept of the designation of an office to coordinate the implementation of the Model Policy developed under Recommendation 1. However, the Ad Hoc Committee did not believe that it is either necessary or useful to assign the coordinating office “government-wide jurisdiction over nearly 30 different categories of test articles—each covered by appropriate regulations governing clinical research. It would be entirely impractical to expect a central HHS office to monitor and evaluate each of these specialized regulations, but it is feasible and desirable that rules governing IRB review and informed consent be consistent throughout all of these regulations and consistent with procedures required by other departments and agencies. As the President’s Commission notes, most departments and agencies already follow the HHS rules pertaining to IRBs and informed consent. To date, uniformity has been developing on a voluntary basis with assistance from OPRR.

Reporting Requirements for Institutions

In consideration of Recommendations 7 and 8 in the Biennial Report, language has been included in Sec. 103(b)(5) to indicate that assurances negotiated with supporting federal agencies or departments must specify

Written procedures for ensuring prompt reporting the IRB, appropriate institutional officials, and the department or agency head (i) any unanticipated problems or scientific misconduct involving risks to human subjects or others; (ii) any allegation or finding of serious or continuing noncompliance with this policy or the requirements or determinations of the IRB; and (iii) any suspension or termination of IRB approval.

This sets forth the requirement that all concerned parties be informed of problems and misconduct based on noncompliance with the Policy for the protection of human subjects. It allows research institutions flexibility in developing procedures compatible with their organizational structures, while requiring them to meet a reasonable standard of accountability. (See discussion of Recommendations 7 and 8, following.)

Role of the Office for Protection from Research Risks (OPPR)

In anticipation of designation of OPRR as a key coordinating office (described below in the Ad Hoc Committee’s response to Recommendation 2), the following responsibility for OPRR has been made explicit in the Model Policy. Sec. 103(f) requires that:

In lieu of negotiating a separate assurance, individual department or agency heads shall accept the existence of a current assurance, appropriate for the research in question, approved by and on file with the Office for Protection from Research Risks, HHS.

This provision will considerably reduce the administrative burden on institutions conducting research and on federal departments and agencies conducting or supporting research. The Ad Hoc Committee, therefore, recommended that the President’s Science Advisor request the Secretary, HHS, to direct the OPRR to exercise federalwide coordination of policies and procedures for the protection of human research subjects. The Model Policy has been drafted to reflect an OPRR role.

The coordinating responsibilities of OPRR include at least the following:

1. OPRR shall continue to negotiate and approve Assurances of Compliance with the HHS regulations based on the Model Policy for HHS conducted and supported research. In lieu of negotiating separate assurances, individual departments and agencies shall accept a current HHS assurance approved by and on file in OPRR if it is appropriate to the research in question.

2. OPRR shall facilitate an exchange of information among all federal departments and agencies that conduct, support or regulate research involving human subjects.

3. OPRR shall, when appropriate, amend and republish the list of categories of research that may be reviewed under the expedited procedures outlined under Sec. 110 of the Model Policy.

4. OPRR shall continue to develop educational materials and programs for the benefit of (a) research investigators; (b) research administrators; (c) IRB members; and (d) federal officials with responsibility for research involving human subjects.

5. Department and agency heads shall forward to OPRR for review and comment all proposed department or agency policies and regulations for the protection of human research subjects. OPRR shall within 90 days of receipt call to the attention of any department or agency issuing a proposed rule or policy any provisions inconsistent with the Model Policy.

(8) The Director, OPRR, shall chair an Interagency Human Subjects Coordinating Committee to facilitate coordination of federal policies and regulations for the protection of human subjects. (This Committee was established in October 1983 by the Director, OSTP, under the auspices of the Federal Coordinating Council for Science, Engineering and Technology and is advisory to department and agency heads.)

"The Ad Hoc Committee believed that if these coordinating steps are taken (including advising, guiding, educating and reviewing as described), the purposes of the recommendations of the President’s Commission will be accomplished. The Interagency Committee is well-positioned to evaluate the implementation of the Model Policy when necessary and appropriate.

The Ad Hoc Committee further believed that over many years the OPRR has established sound credentials in the protection of human subjects. It noted that OPRR has operated effectively with all necessary backing from the Office of the Secretary, HHS. Because OPRR is located in a research milieu, it has ready access to experts in biomedical and behavioral research with experience in dealing with the delicate balance of promoting high quality research while maintaining proper safeguards for human subjects.

By designating OPRR as the coordinating office, the Ad Hoc Committee believed that the Secretary, HHS, would give emphasis to the importance of the coordinating function to be exercised. Establishment of a permanent federalwide advisory group assures the continuation of this emphasis. By designating an existing office in HHS rather than creating a new office, the Secretary is able to accomplish the goals of the President’s Commission with only minimal increases in monetary and personnel expenditures.

Recommendation 3

Each Federal department or agency should have a comprehensive set of rules and procedures governing research with human subjects that applies consistently to all submits within the department or agency.

No action required on Recommendation 3 will be needed if the procedures outlined in response to Recommendations 1 and 2 are adopted.

Recommendation 4

All Federal departments and agencies that conduct or support research with
human subjects should require principal investigators to submit, as part of their annual reports to the IRB and the funding agency, information regarding the number of subjects who participated in each research project as well as the nature and frequency of adverse effects.

The Ad Hoc Committee questioned the feasibility of developing a major data collection of numbers of human subjects who participate in Federally conducted or supported research. It acknowledged the importance of sound data relating to research injuries and adverse reactions and recognized such data would be helpful in making sound policy decisions concerning compensation for research injuries. Nevertheless the Ad Hoc Committee recognized serious definitional problems associated with the collection of such data.

The President’s Commission has acknowledged the difficulty in defining research-related injury. The Veterans Administration (VA) has made efforts to collect data of the type recommended by the President’s Commission. The VA program, as a pilot effort, has been fraught with technical difficulties.

The VA has described certain difficulties recently encountered in collecting data on human research subjects. The VA had issued circulars to its medical centers which were conducting research involving human subjects. The circulars requested that the centers collect data regarding the incidence of adverse results “or effects” of participation in biomedical and behavioral research. The collected data were forwarded to the central VA office. Figures received in November 1981 were forwarded to the central VA office. Figures received in November 1981 provided the VA with unreliable and incomplete reports of human subjects injured or otherwise adversely affected as the result of participation in research projects. Because of definitional problems, misunderstandings on the part of field research personnel, confounding of therapeutic and research data and instances of both underreporting and overreporting the data were considered misleading or meaningless. The data were not amenable to synthesis.

Given the existing definitional problems and the expected poor quality of resulting data, the Ad Hoc Committee believed that the expenditure of scarce resources for data collection was not warranted at this time. In fact, implementation of this recommendation could produce results that are misleading and could generate inappropriate policies and procedures. Therefore, the Ad Hoc Committee recommended that the matter of data collection be addressed by an Interagency Human Subjects Coordinating Committee.

Recommendation 5
The Department of Health and Human Services and all other relevant Federal departments and agencies should proceed promptly to take action on the National Commission’s recommendations concerning research involving children and research involving those institutions as mentally disabled, and other Federal agencies should also act on the final regulations of HHS governing such research.

In early February 1983 HHS Secretary Schweiker approved Subpart D of Title 45 CFR Part 46, “Additional Protections for Children Involved as Subjects in Research.” These were published as a Final Rule in the Federal Register on March 8, 1983, and became effective June 6, 1983. HHS is now considering action on the proposed regulations addressing research involving those institutionalized as mentally disabled.

Recommendation 6
Congress should attach the following condition to any direct appropriations for “private” research entities: “No funds appropriated under this Act may be used, directly or indirectly, to support research involving human subjects unless such research is reviewed and conducted in compliance with either (1) appropriate regulations of (the disbursing agency) or (2) the regulations of the Department of Health and Human Services (45 CFR Part 46).”

The Ad Hoc Committee was unaware of any “private” research entity which receives direct appropriations other than the Gorgas Memorial Institute of Tropical and Preventive Medicine, Inc. OPRR has negotiated an HHS Multiple Project Assurance of Compliance with Gorgas Memorial Institute which has indicated its intention to comply with HHS regulations. Consequently this recommendation has been met by administrative action, and no legislation is required. If other such entities are identified, the federal disbursing agency should arrange for a proper Assurance of Compliance with HHS or Model Policy requirements.

Recommendations 7 and 8
7. 45 CFR 46.103, which specifies the minimum requirements for institutional assurance, should be amended by inserting two new clauses under (b) (5) and (6); to—
• designate a specific office at each institution that will be responsible for: (i) receiving reports of alleged misconduct in research involving human subjects; (ii) investigating promptly and fairly; and (iii) reporting formal findings of misconduct both to the institution’s IRB which approved the research and to the Secretary. The institutional office so designated need not be created specifically for this purpose but may be the relevant IRB itself or another existing office already having responsibility for quality assurance within the institution. Such office shall report on all ongoing investigations of alleged research misconduct involving human subjects as well as formal findings to the IRB, and shall consult with the IRB on all matters relating to the conduct of research with human subjects. (paraphrased)
• require written procedures for insuring prompt reporting to designated institutional officials, and by them to the Secretary, of the results of any investigation or inquiries carried out under the preceding subsection or under Sec. 46.108(c) that reveal research misconduct or serious or continuing noncompliance with Federal or institutional requirements for the protection of human subjects. (paraphrased)

8. 45 CFR 46.108(c) should be revised to read as follows: (In order to fulfill the requirements of these regulations, each IRB shall) (c) be responsible for reporting to the appropriate institutional officials any serious or continuing noncompliance by investigators with the requirements and determinations of the IRB, or with the provisions of the regulations, or with good research practices, that is revealed during the IRB’s continuing or initial review of research or through reports made directly to a member of the IRB or its staff (and that each IRB); (d) establish procedures for receiving and acting upon findings of misconduct in research involving human subjects, made in the office designated pursuant to Sec. 46.103(b)(5). (paraphrased)

After careful review of the recommendations of the President’s Commission, the testimony to the Commissioners leading to these recommendations, and public and interagency comment, the Ad Hoc Committee proposed the following: Sec. 103(b)(5) of the proposed Model Policy requires that in assurances submitted to the Secretary, of the results of any investigation or inquiries carried out under the preceding subsection or under Sec. 46.108(c) that reveal research misconduct or serious or continuing noncompliance with Federal or institutional requirements for the protection of human subjects, the Secretary should proceed promptly to take action to—

serious or continuing noncompliance with this policy or the requirements or
determinations of the IRB, and (iii) any
suspension or termination of IRB approval.

The Ad Hoc Committee concluded that addition of this language would
permit deletion of the current 45 CFR
46.108(c) which states that an IRB
"... be responsible for reporting to the
appropriate institutional officials and
the Secretary any serious or continuing
noncompliance by investigators with the
requirements and determination of the
IRB."

By modification of current language in
the HHS regulations, the Ad Hoc
committee believed that (a) any
implication is eliminated that the IRB is
required to be an investigatory and
reporting body in the institution.
Institutions may develop their own
procedures to assure that allegations are
promptly investigated and reported to
appropriate institutional officials as well as
to supporting federal department or
agency officials, and (b) the
establishment of reporting lines is
assigned to the institutions; and groups
which need to be informed are
identified. Institutions are, therefore,
afforded flexibility in meeting
requirements of the Policy. The
assurance is the appropriate document
for identifying the specific offices to be
notified and the timing and nature of
reporting which may be tailored to each
institution's organizational structure.
The Ad Hoc Committee members noted
that the language proposed in
Recommendations 7 and 8 was perhaps
too detailed for verbatim incorporation into the Model Policy.

Recommendation 9

Federal departments and agencies
should establish government-wide
procedures for making determinations
on suspension and debarment of
grantees and contractors alleged to
have engaged in misconduct in
FederaUy supported research with
human subjects. Final determinations
and sanctions imposed should be
entered onto a consolidated list of
individuals and made known to all
Federal agencies involved with human
research, to state licensing boards, and
to appropriate professional societies.

The Ad Hoc Comment generally
concurred with the recommendation for
the establishment of government-wide
procedures for making determinations
on suspension and debarment of
grantees and contractors alleged to have
engaged in misconduct in federally-
supported research with human
subjects. However, the Ad Hoc
Committee believed that this
recommendation should be carried out
as a part of an Executive Branch
consideration of government-wide
suspension and debarment procedures
encompassing misconduct under all
types of federal support.

The Executive Branch has undertaken
several initiatives in this regard. With
respect to contracts (i.e., procurement)
the Office of Federal Procurement Policy
on the OMB issued, on June 24, 1982, a
Policy Letter setting forth government-
wide policies and procedures for
suspension and debarment of
government contractors and for the
establishment of a consolidated
government-wide listing of these
suspensions and debarments (47 FR
28854). The Policy Letter became
effective on August 30, 1982, and the
General Services Administration
become responsible for maintaining the
consolidated listing of suspensions and
debarments of contractors on that date.
The Policy Letter has now been
incorporated in the Federal Acquisition
Regulation (48 CFR Chapter 1) as
Subpart 9.4, and on February 26, 1985
HHS published implementing
procedures in 48 CFR 309.4.

With respect to grants and other
forms of financial assistance (i.e.,
nonprocurement), on February 18, 1986,
President Reagan signed Executive
Order 12549 mandating the
establishment, under the guidance of
OMB, of a government-wide system for
debarment and suspension from federal
assistance programs. OMB published
proposed Guidelines simultaneously
with the Executive Order, which
provided 60 days opportunity for
comment. OMB is currently reviewing
the comments and expects to publish the
final Guidelines within six months. The
Executive Order calls for implementing
agency regulations within 12 months of
the final OMB Guidelines. This will
result in separate government-wide
procedures for the suspension and
debarment of contractors and of
recipients of financial assistance.

Although federally-supported research
with human subjects is not specifically
mentioned in the government-wide
procedures, one or more of the
specifically stated causes for suspension
and debarment could arise in the course
of such research. The Interagency
Human Subjects Coordination
Committee will monitor any suspension
or debarment actions arising from
research involving human subjects.

Model Federal Policy for Protection of
Human Research Subjects

Sec. 101 To What Does This Policy Apply?
Sec. 102 Definitions.
Sec. 103 Assuring compliance with this
Policy—research conducted or supported
by any Federal Department or Agency.
Sec. 104 Section Reserved.
Sec. 105 Section Reserved.
Sec. 106 Section Reserved.
Sec. 107 IRBmembership.
Sec. 108 IRB functions and operations.
Sec. 109 IRB review of research.
Sec. 110 Expedit ed review procedures for
certain kinds of research involving no
more than minimal risk, and for minor
changes in approved research.
Sec. 111 Criteria for IRB approval of
research.
Sec. 112 Review by institution.
Sec. 113 Suspension or termination of IRB
approval of research.
Sec. 114 Cooperative research.
Sec. 115 IRB Records.
Sec. 116 General requirements for informed
consent.
Sec. 117 Documentation of informed
consent.
Sec. 118 Applications and proposals lacking
definite plans for involvement of human
subjects.
Sec. 119 Research undertaken without the
intention of involving human subjects.
Sec. 120 Evaluation and disposition of
applications and proposals for research to
be conducted or supported by a
Federal Department or Agency.
Sec. 121 Section reserved.
Sec. 122 Use of Federal funds.
Sec. 123 Early termination of research
support; Evaluation of applications and
proposals.
Sec. 124 Conditions.

Sec. 101 To What Does This Policy
Apply?
(a) Except as provided in paragraph
(b) below, this policy applies to all
research involving human subjects
carried out, supported or otherwise
subject to regulation by any federal
department or agency which takes
appropriate administrative action to
make the policy applicable to such
research. This includes research
conducted by federal civilian employees
or military personnel, except that each
department or agency head may adopt
such procedural modifications as may
be appropriate from an administrative
standpoint. It also includes research
conducted, supported, or otherwise
subject to regulation by the Federal
government outside the United States.

(1) Research that is conducted or
supported by a federal department or
agency whether or not it is regulated as
defined in Sec. 102(e) must comply with
all sections of this policy.

(2) Research that is neither conducted
nor supported by a federal department or
agency but is subject to regulation as
defined in Sec. 102(e) must be reviewed
and approved, in compliance with Secs.
101, 102, and 107 through 117 of this
policy, by an institutional review board
(IRB) that operates in accordance with the
pertinent requirements of this policy.
(b) Unless otherwise required by
department or agency heads, research
activities in which the only involvement
of human subjects will be in one or more
of the following categories are exempt
from this policy:
(1) Research conducted in established
or commonly accepted educational
settings, involving normal educational
practices, such as (i) research on regular
and special education instructional
strategies, or (ii) research on the
effectiveness of or the comparison
among instructional techniques,
curricula, or classroom management
methods.
(2) Research involving the use of
educational tests (cognitive, diagnostic,
aptitude, achievement), survey
procedures, interview procedures or
observation of public behavior, unless:
(i) information obtained is recorded in
such a manner that human subjects can
be identified, directly or through
identifiers linked to the subjects; and (ii)
any disclosure of the human subjects’
responses outside the research could
reasonably place the subjects at risk of
criminal or civil liability or be damaging
to the subjects’ financial standing or
employability.
(3) Research involving the use of
educational tests (cognitive, diagnostic,
aptitude, achievement), survey
procedures, interview procedures or
observation of public behavior that is
not exempt under paragraph (2), if: (i)
the human subjects are elected or
appointed public officials or candidates
for public office; or (ii) federal statute(s)
require(s) without exception that the
for public office; or (ii) federal statute(s)
appointed public officials or candidates
not exempt under paragraph (2), if: (i)
observation of public behavior that is
aptitude, achievement), survey
educational tests (cognitive, diagnostic,
diagnostic specimens, or
or classes of research activities
require that specific research activities
or classes of research activities
classified, supported, or otherwise
subject to regulation by the department
or agency but not otherwise covered
by this policy, comply with some or all of
the requirements of this policy.
(e) Compliance with this policy
requires compliance with pertinent
federal laws or regulations which
provide additional protections for
human subjects.
(f) This policy does not affect any
state or local laws or regulations which
may otherwise be applicable and which
provide additional protections for
human subjects.
(g) This policy does not affect any
foreign laws or regulations which may
otherwise be applicable and which
provide additional protections for
human subjects.
(h) When research covered by this
policy takes place in foreign countries:
procedures normally followed in the
foreign countries to protect human
subjects may differ from those set forth
in this policy. [An example is a foreign
institution which complies with
guidelines consistent with the 1975
World Medical Assembly Declaration
(Helsinki II) issued either by sovereign
states or by an organization whose
function for the protection of human
research subjects is internationally
recognized.] In these circumstances, if a
department or agency head determines
that the procedures prescribed by the
institution afford protections that are
at least equivalent to those provided in this
policy, the department or agency head
may approve the substitution of the
foreign procedures in lieu of the
procedural requirements provided in
this policy. Except when otherwise
required by statute, Executive Order, or
the department or agency head, notices
of these actions as they occur will be
published in the Federal Register
or will be otherwise published as provided in
department or agency procedures.
(i) Unless otherwise required by law,
department or agency heads may waive
the applicability of some or all of the
provisions of this policy to specific
research activities or classes of research
activities otherwise covered by this
policy. Except when otherwise required
by statute or Executive Order, the
department or agency head shall
forward advance notices of these
actions to the Office for Protection from
Research Risks, Department of Health
and Human Services (HHS), and shall
also publish them in the Federal Register
or in such other manner as provided in
department or agency procedures:
Sec. 102 Definitions.
(a) “Department or agency head”
means the head of any federal
department or agency and any other
officer or employee of any department
or agency to whom authority has been
delegated.
(b) “Institution” means any public or
private entity or agency (including
federal, state, and other agencies).
(c) “Legally authorized
representative” means an individual or
judicial or other body authorized under
applicable law to consent on behalf of a
prospective subject to the subject’s
participation in the procedure(s)
involved in the research.
(d) “Research” means a systematic
investigation, including research
development, testing and evaluation,
designed to develop or contribute to
generalizable knowledge. Activities
which meet this definition constitute
“research” for purposes of this policy,
whether or not they are conducted under
a program which is considered research
for other purposes. For example, some
“demonstration” and “service”
programs may include research
activities.
(e) “Research subject to regulation,”
and similar terms are intended to
encompass those research activities for
which a federal department or agency
has specific responsibility for regulating
as a research activity, (for example,
Investigational New Drug requirements
administered by the Food and Drug
Administration). It does not include
research activities which are
incidentally regulated by a federal
department or agency solely as part of
the department’s or agency’s broader
responsibility to regulate certain types
of activities whether research or non-
research in nature (for example, Wage
and Hour requirements administered by
the Department of Labor).
(f) “Human subject” means a living
individual about whom an investigator
(whether professional or student)
conducting research obtains (1) data through intervention or interaction with the individual, or (2) identifiable private information. “Intervention” includes both physical procedures by which data are gathered (for example, venipuncture) and manipulations of the subject or the subject’s environment that are performed for research purposes. “Interaction” includes communication or interpersonal contact between investigator and subject. “Private information” includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public (for example, a medical record). Private information must be individually identifiable (i.e., the identity of the subject is or may readily be ascertained by the investigator or associated with the information) in order for obtaining the information to constitute research involving human subjects.

(g) “IRB approval” means the determination of the IRB that the research has been reviewed and may be conducted at an institution within the constraints set forth by the IRB and by other institutional and federal requirements.

(h) “Minimal risk” means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

(i) “Certification” means the official notification by the institution to the supporting department or agency, in accordance with the requirements of this policy, that a research project or activity involving human subjects has been reviewed and approved by an IRB in accordance with an approved assurance.

Sec. 103 Assuring compliance with this Policy—research conducted or support by any Federal Department or Agency.

(a) Each institution engaged in research which is covered by this policy and which is conducted or supported by a federal department or agency shall provide written assurance satisfactory to the department or agency head that it will comply with the requirements set forth in this policy.

(b) Departments and agencies will conduct or support research covered by this policy only if the institution has an assurance approved as provided in this section, and only if the institution has certified to the department or agency head that the research has been reviewed and approved by an IRB provided for in the assurance, and will be subject to continuing review by the IRB. Assurances applicable to federally supported or conducted research shall at a minimum include:

(1) A statement of principles governing the institution in the discharge of its responsibilities for protecting the rights and welfare of human subjects of research conducted at or sponsored by the institution, regardless of whether the research is subject to federal regulation. This may include an appropriate existing code, declaration, or statement of ethical principles, or a statement formulated by the institution itself. This requirement does not preempt provisions of this policy applicable to department- or agency-supported or regulated research and need not be applicable to any research exempted or waived under Secs. 101 (b) or (i).

(2) Designation of one or more IRBs established in accordance with the requirements of this policy, and for which provisions are made for meeting space and sufficient staff to support the IRB’s review and recordkeeping duties.

(3) A list of the IRB members identified by name; earned degrees; representative capacity; indications of experience such as board certifications, licenses, etc., sufficient to describe each member’s chief anticipated contributions to IRB deliberations; and any employment or other relationship between each member and the institution; for example: full-time employee, part-time employee, member of governing panel or board, stockholder, paid or unpaid consultant. Changes in IRB membership shall be reported to the department or agency head.

(4) Written procedures which the IRB will follow (i) for conducting its initial and continuing review of research and for reporting its findings and actions to the investigator and the institution; (ii) for determining which projects require review more often than annually and which projects need verification from sources other than the investigators that no material changes have occurred since previous IRB review; and (iii) for ensuring prompt reporting to the IRB of proposed changes in a research activity, and for ensuring that such changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval except when necessary to eliminate apparent immediate hazards to the subject.

(5) Written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the department or agency head (i) any unanticipated problems of scientific or human subjects; (ii) any allegation or finding of serious or continuing noncompliance with this policy or the requirements or determinations of the IRB; and (iii) any suspension or termination of IRB approval.

(c) The assurance shall be executed by an individual authorized to act for the institution and to assume on behalf of the institution the obligations imposed by this policy and shall be filed in such form and manner as the department or agency head prescribes.

(d) The department or agency head will evaluate all assurances submitted in accordance with this policy through such officers and employees of the department or agency and such experts or consultants engaged for this purpose as the department or agency head determines to be appropriate. The department or agency head’s evaluation will take into consideration the adequacy of the proposed IRB in light of the anticipated scope of the institution’s research activities and the types of subject populations likely to be involved, the appropriateness of the proposed initial and continuing review procedures in light of the probable risks, and the size and complexity of the institution.

(e) On the basis of this evaluation, the department or agency head may approve or disapprove the assurance, or enter into negotiations to develop an approvable one. The department or agency head may limit the period during which any particular approved assurance or class of assurances shall remain effective or otherwise condition or restrict approval.

(f) In lieu of negotiating a separate assurance, individual department or agency heads shall accept the existence of a current assurance, appropriate for the research in question, approved by and on file with the Office for Protection from Research Risks, HHS.

(g) Certification is required when the research is supported by a federal department or agency and not otherwise exempted or waived under Secs. 101 (b) and (i). Along with the submission of an application or proposal for approval or support, an institution with an approved assurance covering the research shall certify that the application or proposal has been reviewed and approved by the IRB. Institutions without an approved assurance covering the research shall certify within 30 days after receipt of a
request for such a certification from the department or agency, that the application or proposal has been approved by the IRB. If the certification is not submitted within these time limits, the application or proposal may be returned to the institution.

Sec. 104 Section reserved.
Sec. 105 Section reserved.
Sec. 106 Section reserved.
Sec. 107 IRB Membership.

(a) Each IRB shall have at least five members, with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution. The IRB shall be sufficiently qualified through the experience and expertise of its members, and the diversity of the members, including consideration of race, gender, and cultural backgrounds and sensitivity to such issues as community attitudes, to promote respect for its advice and counsel in safeguarding the rights and welfare of human subjects. In addition to possessing the professional competence necessary to review specific research activities, the IRB shall be able ascertain the acceptability of proposed research in terms of institutional commitments and regulations, applicable law, and standards of professional conduct and practice. The IRB shall therefore include persons knowledgeable in these areas. If an IRB regularly reviews research that involves a vulnerable category of subjects, such as children, prisoners, pregnant women or mentally disabled persons, consideration shall be given to the inclusion of one or more individuals who are knowledgeable about and experienced in working with these subjects.

(b) Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of men or entirely of women, including the institution’s consideration of qualified persons of both sexes, so long as no selection is made to the IRB on the basis of gender. No IRB may consist entirely of members of one profession.

(c) Each IRB shall include at least one member whose primary concerns are in scientific areas and at least one member whose primary concerns are in nonscientific areas.

(d) Each IRB shall include at least one member who is not otherwise affiliated with the institution and who is not part of the immediate family of a person who is affiliated with the institution.

(e) No IRB may have a member participate in the IRB’s initial or continuing review of any project in which the member has a conflicting interest, except to provide information requested by the IRB.

(f) An IRB may, in its discretion, invite individuals with competence in special areas to assist in the review of issues which require expertise beyond or in addition to that available on the IRB. These individuals may not vote with the IRB.

Sec. 108 IRB functions and operations.

In order to fulfill the requirements of this policy each IRB shall:

(a) Follow written procedures in the same detail as described in Sec. 103(b)(4) and, to the extent required by, Sec. 103(b)(5).

(b) Except when an expedited review procedure is used (see Sec. 110), review proposed research at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in nonscientific areas. In order for the research to be approved, it shall receive the approval of a majority of those members present at the meeting.

Sec. 109 IRB review of research.

(a) An IRB shall review and have authority to approve, require modifications in (to secure approval), or disapprove all research activities covered by this policy.

(b) An IRB shall require that information given to subjects as part of informed consent is in accordance with Sec. 116. The IRB may require that information, in addition to that specifically mentioned in Sec. 116, be given to the subjects when in the IRB’s judgment the information would meaningfully add to the protection of the rights and welfare of subjects.

(c) An IRB shall require documentation of informed consent or may waive documentation in accordance with Sec. 116.

(d) An IRB shall notify investigators and the institution in writing of its decision to approve or disapprove the proposed research activity, or of modifications required to secure IRB approval of the research activity. If the IRB decides to disapprove a research activity, it shall include in its written notification a statement of the reasons for its decision and give the investigator an opportunity to respond in person or in writing.

(e) An IRB shall conduct continuing review of research covered by this policy at intervals appropriate to the degree of risk, but not less than once per year, and shall have authority to observe or have a third party observe the consent process and the research.

Sec. 110 Expedited review procedures for certain kinds of research involving no more than minimal risk, and for minor changes in approved research.

(a) The Secretary, HHS, has established, and published in the Federal Register, a list of categories of research that may be reviewed by the IRB through an expedited review procedure. The list will be amended, as appropriate after consultation with other departments and agencies, through periodic republication by the Secretary, HHS, in the Federal Register.

(b) With the approval of department or agency heads, an IRB may use the expedited review procedure to review either or both of the following: (1) Some or all of the research appearing on the list and found by the reviewers to involve no more than minimal risk, (2) minor changes in previously approved research during the period for which approval is authorized. Under an expedited review procedure, the review may be carried out by the IRB chairperson or by one or more experienced reviewers designated by the chairperson from among members of the IRB. In reviewing the research, the reviewers may exercise all of the authorities of the IRB except that the reviewers may not disapprove the research. A research activity may be disapproved only after review in accordance with the non-expedited procedure set forth in Sec. 108(b).

(c) Each IRB which uses an expedited review procedure shall adopt a method for keeping all members advised of research proposals which have been approved under the procedure.

(d) The department or agency head may restrict, suspend, terminate, or choose not to authorize an institution’s or IRB’s use of the expedited review procedure.

Sec. 111 Criteria for IRB approval of research.

(a) In order to approve research covered by this policy the IRB shall determine that all of the following requirements are satisfied:

(1) Risks to subjects are minimized: (i) By using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk, and (ii) whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes.

(2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result. In evaluating risks
and benefits, the IRB should consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research). The IRB should not consider possible long-range effects of applying knowledge gained in the research (for example, the possible effects of the research on public policy) as among those research risks that fall within the purview of its responsibility.

(3) Selection of subjects is equitable. In making this assessment the IRB should take into account the purposes of the research and the setting in which the research will be conducted and should be particularly cognizant of the special problems of research involving vulnerable populations, such as children, prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged persons.

(4) Informed consent will be sought from each prospective subject or the subject’s legally authorized representative, in accordance with, and to the extent required by Sec. 116.

(5) Informed consent will be appropriately documented, in accordance with, and to the extent required by Sec. 117.

(6) When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.

(7) When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.

(b) When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged persons, additional safeguards have been included in the study to protect the rights and welfare of these subjects.

Sec. 112 Review by institution. Research covered by this policy that has been approved by an IRB may be subject to further appropriate review and approval or disapproval by officials of the institution. However, those officials may not approve the research if it has not been approved by an IRB.

Sec. 113 Suspension or termination of IRB approval of research.

An IRB shall have authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB’s requirements or that has been associated with unexpected serious harm to subjects. Any suspension or termination of approval shall include a statement of the reasons for the IRB’s action and shall be reported promptly to the investigator, appropriate institutional officials, and the department or agency head.

Sec. 114 Cooperative research.

Cooperative research projects are those projects covered by this policy which involve more than one institution. In the conduct of cooperative research projects, each institution is responsible for safeguarding the rights and welfare of human subjects and for complying with this policy. With the approval of the department or agency head, an institution participating in a cooperative project may enter into a joint review arrangement, rely upon the review of another qualified IRB, or make similar arrangements for avoiding duplication of effort.

Sec. 115 IRB records.

(a) An institution, or when appropriate an IRB, shall prepare and maintain adequate documentation of IRB activities, including the following:

(1) Copies of all research proposals reviewed, scientific evaluations, if any, that accompany the proposals, approved sample consent documents, progress reports submitted by investigators, and reports of injuries to subjects.

(2) Minutes of IRB meetings which shall be in sufficient detail to show attendance at the meetings: actions taken by the IRB; the vote on these actions including the number of members voting for, against, and abstaining; the basis for requiring changes in or disapproving research; and a written summary of the discussion of controverted issues and their resolution.

(3) Records of continuing review activities.

(4) Copies of all correspondence between the IRB and the investigators.

(5) A list of IRB members in the same detail as described in Sec. 103(b)(3).

(6) Written procedures for the IRB in the same detail as described in Secs. 103(b)(4) and 103(b)(5).

(b) The records required by this policy shall be retained for at least 3 years, and records relating to research which is conducted shall be retained for at least 3 years after completion of the research. All records shall be accessible for inspection and copying by authorized representatives of the department or agency at reasonable times and in a reasonable manner.

Sec. 116 General requirements for informed consent.

Except as provided elsewhere in this policy, no investigator may involve a human being as a subject in research covered by this policy unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence. The information that is given to the subject or the representative shall be in language understandable to the subject or the representative. No informed consent, whether oral or written, may include any exculpatory language through which the subject or the representative is made to waive or appear to waive any of the subject’s legal rights, or releases or appears to release the investigator, the sponsor, the institution or its agents from liability for negligence.

(a) Basic elements of informed consent. Except as provided in paragraph (c) or (d) below, in seeking informed consent the following information shall be provided to each subject:

(1) A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject’s participation, a description of the procedures to be followed, and identification of any procedures which are experimental;

(2) A description of any reasonably foreseeable risks or discomforts to the subject;

(3) A description of any benefits to the subject or to others which may reasonably be expected from the research;

(4) A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject;

(5) A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained;

(6) For research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained;

(7) An explanation of whom to contact for answers to pertinent questions about
the research and research subjects’ rights, and whom to contact in the event of a research-related injury to the subject; and

(8) A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.

(b) Additional elements of informed consent. When appropriate, one or more of the following elements of information shall also be provided to each subject:

(1) A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable;

(2) Anticipated circumstances under which the subject’s participation may be terminated by the investigator without regard to the subject’s consent;

(3) Any additional costs to the subject that may result from participation in the research;

(4) The consequences of a subject’s decision to withdraw from the research and procedures for orderly termination of participation by the subject;

(5) A statement that significant new findings developed during the course of the research which may relate to the subject’s willingness to continue participation will be provided to the subject; and

(6) The approximate number of subjects involved in the study.

(c) An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth above, or waive the requirement to obtain informed consent provided the IRB finds and documents that:

(1) The research involves no more than minimal risk to the subjects;

(2) The waiver or alteration will not adversely affect the rights and welfare of the subjects;

(3) The research could not practicably be carried out without the waiver or alteration; and

(4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.

Sec. 117 Documentation of informed consent.

(a) Except as provided in paragraph (c) below, informed consent shall be documented by the use of a written consent form approved by the IRB and signed by the subject or the subject’s authorized representative. A copy shall be given to the persons signing the form.

(b) Except as provided in paragraph (c) below, the consent form may be either of the following:

(1) A written consent document that embodies the elements of informed consent required by Sec. 116. This form may be read to the subject or the subject’s legally authorized representative, but in any event, the investigator shall give either the subject or the representative adequate opportunity to read it before it is signed; or

(2) A “short form” written consent document stating that the elements of informed consent required by Sec. 116 have been presented orally to the subject or the subject’s legally authorized representative. When this method is used, there shall be a witness to the oral presentation. Also, the IRB shall approve a written summary of what is to be said to the subject or the representative. Only the short form itself is to be signed by the subject or the representative. However, the witness shall sign both the short form and a copy of the summary, and the person actually obtaining the consent shall sign a copy of the summary. A copy of the summary shall be given to the subject or the representative, in addition to a copy of the “short form.”

(c) An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either:

(1) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be asked whether the subject wants documentation linking the subject with the research, and the subject’s wishes will govern; or

(2) That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context.

In cases in which the documentation requirement is waived, the IRB may require the investigator to provide subjects with a written statement regarding the research.

Sec. 118 Applications and proposals lacking definite plans for involvement of human subjects.

Certain types of applications for grants, cooperative agreements, or contracts are submitted to departments or agencies with the knowledge that subjects may be involved within the period of support, but definite plans would not normally be set forth in the application or proposal. These include activities such as institutional type grants when selection of specific projects is the institution’s responsibility; research training grants in which the activities involving subjects remain to be selected and projects in which human subjects’ involvement will depend upon completion of instruments, prior animal studies, or purification of compounds. These applications need not be reviewed by an IRB before an award may be made. However, except for research exempted or waived under Sec. 101 (b) or (i), no human subjects may be involved in any project supported by these awards until the project has been reviewed and approved by the IRB, as provided in this policy, and certification submitted to the department or agency.

Sec. 119 Research undertaken without the intention of involving human subjects.

In the event research is undertaken without the intention of involving human subjects, but it is later proposed to involve human subjects in the research, the research shall first be reviewed and approved by an IRB, as provided in this policy, a certification submitted to the department or agency, and final
approval given to the proposed change
by the department or agency.

Sec. 120 Evaluation and disposition of
applications and proposals for research
to be conducted or supported by a
Federal Department or Agency.

(a) The department or agency head
will evaluate all applications and
proposals involving human subjects
submitted to the department or agency
through such officers and employees of
the department or agency and such
experts and consultants as the
department or agency head determines
to be appropriate. This evaluation will
take into consideration the risks to the
subjects, the adequacy of protection
against these risks, the potential
benefits of the research to the subjects
and others, and the importance of the
knowledge gained or to be gained.

(b) On the basis of this evaluation, the
department or agency head may
approve or disapprove the application or
proposal, or enter into negotiations to
develop an approvable one.

Sec. 121 Section reserved.

Sec. 122 Use of Federal funds.

Federal funds administered by a
department or agency may not be
expended for research involving human
subjects unless the requirements of this
policy have been satisfied.

Sec. 123 Early termination of research
support; Evaluation of applications and
proposals.

(a) The department or agency head
may require that department or agency
support for any project be terminated or
suspended in the manner prescribed in
applicable program requirements, when
the department or agency head finds an
institution has materially failed to
comply with the terms of this policy.

(b) In making decisions about
supporting or approving applications or
proposals covered by this policy the
department or agency head may take
into account, in addition to all other
eligibility requirements and program
criteria, factors such as whether the
applicant has been subject to a
termination or suspension under
paragraph (a) of this section and
whether the applicant or the person who
would direct or has directed the
scientific and technical aspects of an
activity has in the judgment of the
department or agency head materially
failed to discharge responsibility for the
protection of the rights and welfare of
human subjects (whether or not the
research was subject to federal
regulation).

Sec. 124 Conditions.

With respect to any research project
or any class of research projects the
department or agency head may impose
additional conditions prior to or at the
time of approval when in the judgment
of the department or agency head
additional conditions are necessary for
the protection of human subjects.

Concurrences of Departments and
Agencies Including Proposed Departures
From the Model Policy

No Departures

Agency for International Development
(AID)
Consumer Product Safety Commission
(CPSC)
Department of Agriculture (USDA)
Department of Commerce (DOC)
Department of Defense (DOD)
Department of Energy (DOE)
Department of Housing and Urban
Development (HUD)
Department of Justice (DOJ)
Department OfTransportation (DOT)
Environmental Protection Agency (EPA)
National Aeronautics and Space
Administration (NASA)
National Science Foundation (NSF)

Comment

Central Intelligence Agency (CIA)

The Central Intelligence Agency (CIA)

is required by Executive Order 12333
to conform to the guidelines issued by the
Department of Health and Human
Services (HHS). Currently, the CIA
follows the HHS regulations codified in
45 CFR Part 46. If, with respect to the
CIA, HHS incorporates the Model
Policy, the CIA will follow the model
policy. The CIA fully concurs with the
principles established in the Model
Policy.

Proposed Departures

Department of Education (ED)

A departure for ED only that pertains
only to research involving the use of
educational tests, survey procedures,
interview procedures, or observation of
public behavior, conducted under a
program subject to the General
Education Provisions Act: Revise the
exception to the Model Policy stated in
Section 101(b)(3)(ii) to read as follows:

“The research is conducted under a
program subject to the protections of the
General Education Provisions Act
(GEPA), including GEPA Sections 400A
(20 U.S.C. 1221-3), 438 (20 U.S.C. 1232g),
and 439 (20 U.S.C. 1232h).”

Department of Health and Human
Services (HHS)

1. Section 101(b)(6) of the HHS
regulations (which becomes Section
101(b)(5) of the Model Policy) now has a
qualifier found at 45 CFR 46.101(i): “(i) If,
following review of proposed research
activities that are exempt from these
regulations under paragraph (b)(6), [of
the HHS regulations] the Secretary
determines that a research or
demonstration project presents a danger
to the physical, mental, or emotional
well-being of a participant or subject of
the research or demonstration project
then federal funds may not be expended
for such a project without the written
informed consent of each participant or
subject.”

HHS intends to retain this qualifier to
exemption 6 in future regulations.

2. Section 103(g)—The Model Policy
requires that institutions holding an
approved assurance which covers a
proposed research projects submit
certification of IRB review and approval
along with an application for funding.
Current HHS regulations permit
institutions to submit such certification
along with the application or within 60
days of application for funding [45 CFR
46.163(f)]. At the time HHS publishes
proposed rules and technical
amendments designed to implement the
Model Policy, HHS will request
comment on whether or not the “60-day
grace period” should be reduced or
eliminated.

Food and Drug Administration (FDA)

1. Section 101(h)—The section of the
Model Policy addresses research that
takes place in foreign countries. FDA
must diverge from the Model Policy with
regard to those clinical investigations
that take place in a foreign country and
are conducted under a research permit
granted by FDA. Such investigations
must be carried out in accordance with
the Federal Food, Drug, and Cosmetic
Act (FD&C Act), which establishes
certain requirements for the conduct of
such investigations [see, e.g., 21 U.S.C.
355(i), 357(d)(3), and 360j(g)]. For these
investigations, FDA does not have the
authority to accept the procedures
followed in a foreign country in lieu of
the procedures required by the FD&C
Act.

2. Section 116(d)—This section of the
Model Policy permits altering or waiving
of the informed consent requirements.
FDA must depart from this provision of
the Model Policy (See 21 CFR 50.20). The
FD&C Act requires that informed

consent be obtained from all subjects of clinical investigations except in very limited circumstances [see e.g., 21 U.S.C. 355(i), 357(d)(3), and 360j(g)(3)(D)], which establish requirements for the conduct of clinical investigations for drugs, antibiotic drugs, and medical devices, respectively. FDA does not have authority under the FD&C Act to waive this requirement.

Veterans Administration (VA)

VA will continue intramural research and development practices of not permitting exempted research [Section 101(2)(b)] or expedited review (Section 110), not permitting waiver of informed consent [Section 116(c)] or “short form” written consent [Section 117(b)(2)], and not requiring written institutional assurances from VA medical centers [Section 103(a)]. Further, regarding cooperative research efforts under Section 114, VA requires that each VA medical center which participates in a cooperative or multi-hospital project must obtain the approval of its own Human Studies Subcommittee for such research.

[FR Doc. 86-12386 Filed 5–24-86; 4:21 pm]

BILLING CODE 4140-01-M